Biogen Inc. stock (US09062X1037): Goldman Sachs lifts target after strong Q1 and Leqembi momentum

Biogen Inc. has surprised with stronger-than-expected Q1 2026 earnings and accelerating Leqembi sales. Goldman Sachs reacted by raising its price target to 250 USD, putting the Alzheimer’s pipeline and guidance in sharper focus for US investors.

Biogen Inc. has moved back into the spotlight after reporting better-than-expected Q1 2026 results and seeing renewed momentum in its Alzheimer’s therapy Leqembi. The company posted revenue of 2.48 billion USD, up about 2% year over year, and non?GAAP earnings per share of 3.57 USD, clearly ahead of the 2.95 USD consensus estimate, according to earnings coverage on 05/15/2026 (MarketBeat as of 05/17/2026). At the same time, Leqembi generated 168 million USD in global in?market sales in the quarter, a jump of roughly 74% versus the prior?year period, based on figures cited from the Q1 2026 earnings transcript on 05/15/2026 (TheStreet as of 05/16/2026).

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Biogen Inc.
• Sector/industry: Biotechnology / pharmaceuticals
• Headquarters/country: Cambridge, Massachusetts, United States
• Core markets: Neurology, neurodegenerative and rare diseases with a strong presence in the US and key international markets
• Key revenue drivers: Multiple sclerosis therapies, Alzheimer’s drug Leqembi, spinal muscular atrophy treatment Spinraza and biosimilars portfolio
• Home exchange/listing venue: Nasdaq (ticker: BIIB)
• Trading currency: USD

Biogen Inc.: core business model

Biogen Inc. is a large US biotechnology group focused on therapies for neurological and neurodegenerative diseases, areas where medical need and pricing power can be high but clinical risk is significant. The company has historically been best known for its multiple sclerosis drugs and for pioneering work in neurology, which generated substantial cash flows that funded a broad research and development pipeline as the biotech sector expanded in the US.

Over the past decade, Biogen Inc. has increasingly repositioned its strategy toward Alzheimer’s disease and other neurodegenerative disorders as its core multiple sclerosis franchise has come under pressure from competition and patent expiries. This pivot has involved substantial R&D spending, high?profile partnerships and headline?grabbing regulatory decisions, reflecting both the potential size of the market and the execution risks involved. For US investors, this evolution means that the investment story is now more tightly linked to late?stage clinical outcomes and regulatory milestones than in earlier years.

Biogen Inc. generates revenue primarily from branded specialty therapies, which are typically high?value drugs treating chronic and severe conditions. The company also participates in biosimilars, providing a more diversified portfolio and some cushioning against volatility in any single product category. However, the clear strategic emphasis today lies in neurology, especially Alzheimer’s, where Leqembi and the company’s next?generation pipeline hold the promise of long?term growth if clinical and commercial expectations are met.

Main revenue and product drivers for Biogen Inc.

The latest quarterly data underline how Biogen Inc.’s revenue mix is shifting. In Q1 2026 the group reported revenue of 2.48 billion USD, marking about 2% year?over?year growth, while non?GAAP EPS of 3.57 USD comfortably topped the 2.95 USD consensus estimate, according to a recap of the results published on 05/15/2026 (TheStreet as of 05/16/2026). Management also raised its full?year 2026 guidance to a non?GAAP EPS range of 14.25–15.25 USD, as referenced in a separate summary on 05/17/2026 (MarketBeat as of 05/17/2026).

Leqembi, developed with partner Eisai, has emerged as Biogen Inc.’s most closely watched asset. For Q1 2026, global in?market Leqembi sales reached 168 million USD, representing roughly 74% growth versus the same quarter a year earlier, based on figures cited from the company’s earnings call on 05/15/2026 (Ad?hoc-news as of 05/16/2026). This trajectory suggests that the commercial roll?out is gaining steam from a relatively low base, with uptake in the US market particularly important given reimbursement and infrastructure requirements for Alzheimer’s treatments.

Beyond Leqembi, Biogen Inc. still derives a significant share of revenue from its established multiple sclerosis portfolio and from Spinraza in spinal muscular atrophy. However, these older pillars face structural headwinds, including generic erosion and intensifying competition, which are expected to drive an overall mid?single?digit revenue decline in 2026 even as newer products grow, according to commentary summarizing the company’s outlook on 05/16/2026 (TheStreet as of 05/16/2026). This dynamic underscores why markets are so focused on the scale and speed of Leqembi’s ramp and on the performance of pipeline assets.

The pipeline includes a next?generation Alzheimer’s candidate that has shown promising Phase 2 data, including evidence of tau reduction and potential cognitive benefit, as reported in detailed analyst commentary on 05/16/2026 (Dealroom as of 05/16/2026). In parallel, Biogen Inc. and partner Ionis Pharmaceuticals recently highlighted topline Phase 2 CELIA data for diranersen in Alzheimer’s disease, which were described as compelling by Ionis in a news release dated 05/14/2026 (Ionis as of 05/14/2026). If these programs progress successfully into late?stage development, they could broaden Biogen Inc.’s Alzheimer’s franchise and potentially extend its competitive lead.

On the financial side, Biogen Inc.’s raised 2026 EPS guidance signals confidence in cost discipline and in the revenue contribution from newer assets. Nevertheless, commentary from industry observers points out that the company’s overall top line is still expected to contract in 2026 because of legacy erosion, while the recent Apellis deal adds leverage to the balance sheet, as summarized in sector analysis on 05/16/2026 (Ad?hoc-news as of 05/16/2026). The net result is a business where growth is increasingly concentrated in a smaller number of key assets, amplifying both upside potential and downside risk for shareholders.

Goldman Sachs raises price target after Q1 beat

The Q1 2026 earnings beat and the acceleration in Leqembi sales prompted a notable reaction from Wall Street. Goldman Sachs analyst Salveen Richter raised the bank’s price target on Biogen Inc. shares from 238 USD to 250 USD while maintaining a buy rating, according to a report referencing MarketScreener data published on 05/16/2026 (TheStreet as of 05/16/2026). The revised target reflects Goldman’s view that Leqembi’s commercial momentum is solid and that the company’s next?generation Alzheimer’s pipeline could meaningfully expand the addressable market over the next 18 months if key catalysts break in Biogen’s favor.

Goldman’s move comes against a backdrop of generally constructive analyst sentiment. A recent survey of broker opinions showed that Biogen Inc. carries a Moderate Buy consensus rating, with an average price target of 215.62 USD based on multiple analyst models summarized on 05/17/2026 (MarketBeat as of 05/17/2026). That average target sits below Goldman’s 250 USD level, highlighting that the bank’s assumptions about the trajectory of Leqembi and the pipeline appear more optimistic than the broader street view.

From a share price perspective, Biogen Inc. stock has already undergone a significant rerating over the last year. The shares have climbed from a 52?week low of about 119 USD to nearly 206 USD, with the bulk of the gains occurring as Leqembi’s commercial performance improved and as several analysts lifted their price targets in response, according to performance data compiled in a detailed review on 05/16/2026 (TheStreet as of 05/16/2026). Against this backdrop, Goldman’s 250 USD target implies mid?teens percentage upside from recent trading levels, but it also assumes that several scientific and regulatory milestones land on schedule.

The rationale behind the higher target is closely tied to specific growth drivers. In Goldman’s view, a 74% year?over?year rise in Leqembi revenue, growing indications that the drug is taking a leadership position over Eli Lilly’s rival therapy Kisunla, and encouraging data from Biogen Inc.’s next?generation Alzheimer’s drug collectively support a more constructive long?term earnings profile, as outlined in analysis referencing MarketScreener on 05/16/2026 (Dealroom as of 05/16/2026). For investors following the name on Nasdaq, these details help frame how sensitive the valuation has become to incremental news around Alzheimer’s sales trends and clinical trial outcomes.

Why Biogen Inc. matters for US investors

For US investors, Biogen Inc. represents one of the most prominent pure?play opportunities in neurology and Alzheimer’s disease on a major domestic exchange. The shares trade on Nasdaq under the ticker BIIB, providing deep liquidity and access via standard US brokerage platforms. As the company’s growth prospects increasingly hinge on Alzheimer’s therapies, Biogen Inc. has become a bellwether for how quickly disease?modifying treatments can gain real?world traction in the US healthcare system, where factors such as Medicare reimbursement, diagnostic capacity and infusion infrastructure all play crucial roles.

Biogen Inc.’s progress is also relevant from a portfolio construction perspective. The stock can serve as an example of late?stage biotech risk and reward in the US market: on one side are large potential revenue streams from successful neurodegenerative therapies; on the other side are binary?type events such as pivotal trial readouts or regulatory decisions that can materially reprice expectations. The US investor base therefore tends to scrutinize not only headline earnings, but also qualitative details from earnings calls, FDA interactions and collaboration announcements with partners like Eisai and Ionis.

Additionally, Biogen Inc.’s strategic shift toward Alzheimer’s has implications for broader US healthcare trends. If Leqembi and successor therapies continue to scale, payers, hospitals and diagnostic providers in the United States will need to adapt capacity for earlier diagnosis and treatment of cognitive decline. This could have knock?on effects in related sectors, from imaging equipment to long?term care planning. For many US?based investors who follow healthcare and biotech, Biogen Inc. therefore sits at the intersection of scientific innovation, policy decisions and demographic change, making its quarterly updates and analyst reactions a recurring focal point.

Conclusion

Biogen Inc. enters the rest of 2026 with a complex but closely watched investment profile. The company has delivered a Q1 2026 earnings beat, raised its full?year EPS guidance and reported 74% year?over?year growth in Leqembi sales to 168 million USD, according to summaries of the quarter and subsequent commentary on 05/15/2026 and 05/16/2026 (MarketBeat as of 05/17/2026; TheStreet as of 05/16/2026). Goldman Sachs’ decision to lift its price target from 238 USD to 250 USD underscores how crucial Alzheimer’s momentum and pipeline progress have become for the equity story. At the same time, ongoing declines in the legacy multiple sclerosis franchise, added leverage from acquisitions and dependence on future regulatory decisions create meaningful uncertainties. For US investors, Biogen Inc. remains a high?profile neurology name where sentiment is likely to swing with each new data release, reimbursement update and analyst revision.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.